.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Julphar
Mallinckrodt
Argus Health
McKesson
US Army
Chubb
AstraZeneca
Federal Trade Commission
Daiichi Sankyo

Generated: September 26, 2017

DrugPatentWatch Database Preview

Forest Labs Llc Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS LLC, and what generic alternatives to FOREST LABS LLC drugs are available?

FOREST LABS LLC has ten approved drugs.

There are thirty-five US patents protecting FOREST LABS LLC drugs and there have been six Paragraph IV challenges on FOREST LABS LLC drugs in the past three years.

There are three hundred and sixty patent family members on FOREST LABS LLC drugs in forty-five countries.

Summary for Applicant: Forest Labs Llc

Patents:35
Tradenames:9
Ingredients:8
NDAs:10
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
LINZESS
linaclotide
CAPSULE;ORAL202811-003Jan 25, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
SAPHRIS
asenapine maleate
TABLET;SUBLINGUAL022117-003Mar 12, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-002Jun 21, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-002Jun 21, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-001Dec 23, 2014ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs Llc

Paragraph IV activity for FOREST LABS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
nebivolol hydrochloride and valsartan
Tablets5 mg/80 mg
BYVALSON
6/9/2017
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules7 mg/10 mg
NAMZARIC
9/26/2016
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules21 mg/10 mg
NAMZARIC
9/23/2016
linaclotide
Capsules145 mcg and 290 mcg
LINZESS
8/30/2016
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules14 mg/10 mg and 28 mg/10 mg
NAMZARIC
5/18/2015
vilazodone hydrochloride
Tablets10 mg, 20 mg, and 40 mg
VIIBRYD
1/21/2015
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
Capsules140 mg/125 mg/ 125 mg
PYLERA  
8/12/2014
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
8/16/2013
asenapine maleate
Sublingual Tablets5 mg and 10 mg
SAPHRIS
8/13/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg
NAMENDA XR
6/17/2013
memantine hydrochloride
Extended-release Capsules28 mg
NAMENDA XR
6/12/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
6/10/2013
mesalamine
Suppository1000 mg
CANASA
5/24/2013
memantine hydrochloride
Tablets5 mg and 10 mg
NAMENDA
10/16/2007

Non-Orange Book Patents for Forest Labs Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,624,204Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
7,772,188Methods and compositions for the treatment of gastrointestinal disorders► Subscribe
7,541,384Mesalamine suppository► Subscribe
7,381,726Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
2,014,073,571► Subscribe
8,927,552Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,619,007Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
8,318,744Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
8,921,375Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
7,910,546Methods and compositions for the treatment of gastrointestinal disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Llc Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006130174► Subscribe
Portugal1911763► Subscribe
Canada2451028► Subscribe
Canada2558050► Subscribe
African Regional IP Organization (ARIPO)200704273► Subscribe
SloveniaEP1911763► Subscribe
Canada2569881► Subscribe
Canada2315408► Subscribe
China102970971► Subscribe
Australia2004210161► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Forest Labs Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00026Denmark► Subscribe
0594Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
2013014Lithuania► SubscribePRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
00594Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
00593Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
C/GB02/046United Kingdom► SubscribePRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
90024-6Sweden► SubscribePRODUCT NAME: LINAKLOTID; REG. NO/DATE: EU/1/12/801/001 20121126
201Luxembourg► SubscribePRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUICI,PROTETE PAR LE BREVET DE BASE,Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES
C/GB97/023United Kingdom► SubscribePRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
C/GB96/048United Kingdom► SubscribePRODUCT NAME: NEBIVOLOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE; REGISTERED: NL RVG/19317 19951018; UK 00242/0309 19960509
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
McKinsey
Farmers Insurance
Daiichi Sankyo
Dow
Medtronic
Mallinckrodt
Baxter
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot